Payment overview · 2025
General Payments
$686.17
11 reported records · 10 companies
Healthcare provider profile · identity verified
Mohit Srivastava, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BUNKIE, LA · NPI 1619945656
Verified facts
What the public records show
CMS Open Payments records show Mohit Srivastava, MD received $686.17 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.46 | 33.7% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $129.00 | 18.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.76 | 16.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $92.88 | 13.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $34.73 | 5.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.69 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.44 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.74 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.22 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.25 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $686.17 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $231.46 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $129.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $111.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $92.88 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 379 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 67 |
| Simvastatin | Simvastatin | 289 | 59 |
| Lisinopril | Lisinopril | 265 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 238 | 68 |
| Gabapentin | Gabapentin | 188 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 179 | 38 |
| Alprazolam | Alprazolam | 150 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 30 |
| Furosemide | Furosemide | 142 | 38 |
| Potassium Chloride | Potassium Chloride | 134 | 44 |
| Trazodone Hcl | Trazodone Hcl | 128 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 28 |
| Metformin Hcl | Metformin Hcl | 112 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 26 |
| Azithromycin | Azithromycin | 104 | 70 |
| Losartan Potassium | Losartan Potassium | 93 | 29 |
| Meloxicam | Meloxicam | 93 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 16 |
| Carvedilol | Carvedilol | 87 | 21 |
| Eliquis | Apixaban | 84 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 27 |
| Omeprazole | Omeprazole | 78 | 22 |
| Tramadol Hcl | Tramadol Hcl | 77 | 17 |
| Famotidine | Famotidine | 72 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 23 |
| Clonidine Hcl | Clonidine Hcl | 66 | 15 |
| Montelukast Sodium | Montelukast Sodium | 59 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Sucralfate | Sucralfate | 54 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 46 |
| Temazepam | Temazepam | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Methylprednisolone | Methylprednisolone | 48 | 38 |
| Jardiance | Empagliflozin | 46 | 11 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 13 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Glimepiride | Glimepiride | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Phenobarbital | Phenobarbital | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 11 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 11 |
| Finasteride | Finasteride | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Naproxen | Naproxen | 18 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 13 |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lessina | Levonorgestrel/Ethin.Estradiol | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $686.17 · 11 records | Novo Nordisk Inc | CAPLYTA, Cologuard Collection Kit, FLOWTRIEVER, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, Ozempic, REPATHA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error